Respiratory Syncytial Virus Therapeutics Market, By Treatment Type, By Dosage Form, By Age Group, By Distribution Channel, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

Description

REPORT HIGHLIGHT

Respiratory Syncytial Virus Therapeutics Market size was valued at US$ 1,590.32 Million in 2024, expanding at a CAGR of 15.50% from 2025 to 2032.

The Respiratory Syncytial Virus (RSV) therapeutics market focuses on treatments and preventive solutions for RSV infections, which primarily affect infants, older adults, and immunocompromised individuals. This market includes antiviral drugs, monoclonal antibodies, and vaccines aimed at reducing disease severity and transmission. The increasing prevalence of RSV, along with rising hospitalizations, has driven demand for effective therapies. Governments and pharmaceutical companies are investing in research to develop advanced treatments, including long-acting monoclonal antibodies and novel antivirals. Regulatory approvals for RSV vaccines, especially for high-risk groups, have expanded the market.

Advancements in diagnostic techniques support early detection and timely intervention. North America and Europe dominate due to strong healthcare infrastructure and high awareness while emerging economies show growing adoption. Market growth is further supported by collaborations between biotech firms and healthcare organizations. The introduction of cost-effective therapies is expected to enhance accessibility worldwide, ensuring better disease management.

Respiratory Syncytial Virus Therapeutics Market- Market Dynamics

Increasing adoption of long-acting monoclonal antibodies for infant RSV protection.

The increasing adoption of long-acting monoclonal antibodies for infant RSV protection is a key driver of the RSV therapeutics market. Traditional monoclonal antibodies, such as Palivizumab, required monthly dosing, limiting their accessibility and compliance. However, newer long-acting antibodies like Nirsevimab offer extended protection with a single dose, making them more convenient and cost-effective. Governments and healthcare organizations are actively recommending these therapies for high-risk infants to reduce RSV-related hospitalizations. The high burden of RSV infections in newborns and premature babies has led to expanded immunization programs. Additionally, regulatory approvals and funding for long-acting monoclonal antibodies are increasing their availability in developed and emerging markets. As these therapies become more integrated into routine infant care, they are expected to drive market growth significantly.

Respiratory Syncytial Virus Therapeutics Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 15.50% over the forecast period (2025-2032)

Based on Treatment Type segmentation, monoclonal antibodies were predicted to show maximum market share in the year 2024

Based on Dosage Form segmentation, injectable was the leading Dosage Form in 2024

Based on Age Group segmentation, Infants & Young Children was the leading Age Group in 2024

Based on Distribution Channel segmentation, Hospitals & Clinics was the leading Distribution Channel in 2024

based on region, North America was the leading revenue generator in 2024

Respiratory Syncytial Virus Therapeutics Market- Segmentation Analysis:

The Global Respiratory Syncytial Virus Therapeutics Market is segmented based on Treatment Type, Dosage Form, Age Group, Distribution Channel, and Region.

The market is divided into three categories based on Treatment Type: Antiviral Drugs, Monoclonal Antibodies, and Vaccines. The monoclonal antibodies segment dominates the Respiratory Syncytial Virus (RSV) therapeutics market due to their effectiveness in preventing severe RSV infections, especially in high-risk groups like infants and older adults. Palivizumab has been widely used for years, and the recent approval of long-acting monoclonal antibodies such as Nirsevimab has further strengthened this segment. These treatments provide passive immunity, reducing RSV-related hospitalizations and complications. The increasing burden of RSV infections, along with government recommendations for monoclonal antibody use in vulnerable populations, has fueled demand. Pharmaceutical companies continue to invest in developing next-generation monoclonal antibodies with improved efficacy and longer duration of action. Additionally, the high cost of these therapies contributes significantly to market revenue. North America and Europe lead in adoption due to strong healthcare infrastructure and reimbursement policies. As new antibody formulations receive regulatory approvals, this segment is expected to maintain its dominance in the RSV therapeutics market.

The market is divided into three categories based on Dosage Form: Oral, Injectable, and Inhalation. The injectable segment dominates the Respiratory Syncytial Virus (RSV) therapeutics market due to the widespread use of monoclonal antibodies and vaccines, which are primarily administered via injection. Monoclonal antibodies like Palivizumab and Nirsevimab, as well as newly approved RSV vaccines for older adults, rely on injectable formulations for effective delivery. This route ensures precise dosing, rapid absorption, and prolonged protection, making it the preferred choice for high-risk populations. The rising incidence of severe RSV infections among infants and older adults has led to increased adoption of injectable treatments. Additionally, government immunization programs and hospital protocols favor injectable RSV therapies, further boosting this segment. North America and Europe lead in injectable RSV therapeutics due to strong healthcare infrastructure and high vaccine coverage. As more long-acting monoclonal antibodies and RSV vaccines gain approval, the injectable segment is expected to maintain its dominance.

Respiratory Syncytial Virus Therapeutics Market- Geographical Insights

North America dominates the Respiratory Syncytial Virus (RSV) therapeutics market due to high awareness, strong healthcare infrastructure, and widespread adoption of monoclonal antibodies and vaccines. The U.S. leads the region, with government-backed immunization programs and regulatory approvals for advanced RSV therapies like Nirsevimab and RSV vaccines for older adults. Increasing RSV-related hospitalizations among infants and elderly populations have driven demand for effective treatments. Additionally, major pharmaceutical companies are investing in research and development to introduce next-generation monoclonal antibodies. Favorable reimbursement policies and high healthcare spending further support market growth in the region.

The United States holds the largest share of the Respiratory Syncytial Virus (RSV) therapeutics market due to its advanced healthcare infrastructure, high disease awareness, and strong government support. The CDC and FDA have approved RSV vaccines for older adults and long-acting monoclonal antibodies like Nirsevimab for infant protection, driving widespread adoption. Rising RSV-related hospitalizations, particularly among infants and the elderly, have increased demand for effective treatments. Government-backed immunization programs and reimbursement policies further boost market growth. Additionally, pharmaceutical companies are heavily investing in research and clinical trials to develop next-generation RSV therapeutics. The country's high healthcare spending and robust regulatory framework ensure continued market expansion.

Respiratory Syncytial Virus Therapeutics Market- Competitive Landscape:

The competitive landscape of the Respiratory Syncytial Virus (RSV) therapeutics market is characterized by intense research and development (R&D) efforts, strategic collaborations, and regulatory approvals. Leading pharmaceutical companies focus on developing monoclonal antibodies, vaccines, and antiviral drugs to address the growing burden of RSV infections. The market is dominated by AstraZeneca, Sanofi, Pfizer, GSK, and Moderna, which have introduced or are developing innovative RSV therapeutics.

Key players are leveraging strategic partnerships and acquisitions to expand their product portfolios, as seen in Pfizer's acquisition of ReViral for RSV antiviral development. The approval of long-acting monoclonal antibodies like Nirsevimab and RSV vaccines for older adults has intensified competition. Companies are also focusing on clinical trials, government collaborations, and pricing strategies to strengthen their market position. With increasing demand for RSV prevention and treatment, the competitive landscape is expected to evolve with new entrants and advanced therapeutic solutions.

Recent Developments:

In February 2024, GSK plc announced that the U.S. Food and Drug Administration (FDA) granted priority review for an application to expand the indication of its combined respiratory syncytial virus (RSV) vaccine to individuals aged 50 to 59 at higher risk of RSV illness.

In May 2023, Pfizer Inc. stated that the U.S. Food and Drug Administration (FDA) approved ABRYSVO, its bivalent RSV prefusion F (RSVpreF) vaccine, for preventing lower respiratory tract illness caused by RSV in individuals aged 60 and older. This strategy has contributed to the company's revenue growth.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

AstraZeneca plc
Sanofi S.A.
Pfizer Inc.
Moderna, Inc.
GSK plc
Merck & Co., Inc.
Johnson & Johnson
Novavax, Inc.
Bavarian Nordic A/S
Enanta Pharmaceuticals, Inc.
BioNTech SE
Meissa Vaccines, Inc.
Codagenix, Inc.
Alnylam Pharmaceuticals, Inc.
Vaxart, Inc.
Icosavax, Inc.

GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTICS MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2019 - 2032

Antiviral Drugs
Monoclonal Antibodies
Vaccines

GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTICS MARKET, BY DOSAGE FORM- MARKET ANALYSIS, 2019 - 2032

Oral
Injectable
Inhalation

GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTICS MARKET, BY AGE GROUP- MARKET ANALYSIS, 2019 - 2032

Infants & Young Children
Adults
Older Adults (65+ years)

GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

Hospitals & Clinics
Retail Pharmacies
Online Pharmacies

GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA

Product Code: ANV4937

1. Respiratory Syncytial Virus Therapeutics Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Respiratory Syncytial Virus Therapeutics Market Snippet by Treatment Type
- 2.1.2. Respiratory Syncytial Virus Therapeutics Market Snippet by Dosage Form
- 2.1.3. Respiratory Syncytial Virus Therapeutics Market Snippet by Age Group
- 2.1.4. Respiratory Syncytial Virus Therapeutics Market Snippet by Distribution Channel
- 2.1.5. Respiratory Syncytial Virus Therapeutics Market Snippet by Country
- 2.1.6. Respiratory Syncytial Virus Therapeutics Market Snippet by Region
2.2. Competitive Insights

3. Respiratory Syncytial Virus Therapeutics Key Market Trends

3.1. Respiratory Syncytial Virus Therapeutics Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Respiratory Syncytial Virus Therapeutics Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Respiratory Syncytial Virus Therapeutics Market Opportunities
3.4. Respiratory Syncytial Virus Therapeutics Market Future Trends

4. Respiratory Syncytial Virus Therapeutics Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Respiratory Syncytial Virus Therapeutics Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Respiratory Syncytial Virus Therapeutics Market Landscape

6.1. Respiratory Syncytial Virus Therapeutics Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Respiratory Syncytial Virus Therapeutics Market - By Treatment Type

7.1. Overview
- 7.1.1. Segment Share Analysis, By Treatment Type, 2024 & 2032 (%)
- 7.1.2. Antiviral Drugs
- 7.1.3. Monoclonal Antibodies
- 7.1.4. Vaccines

8. Respiratory Syncytial Virus Therapeutics Market - By Dosage Form

8.1. Overview
- 8.1.1. Segment Share Analysis, By Dosage Form, 2024 & 2032 (%)
- 8.1.2. Oral
- 8.1.3. Injectable
- 8.1.4. Inhalation

9. Respiratory Syncytial Virus Therapeutics Market - By Age Group

9.1. Overview
- 9.1.1. Segment Share Analysis, By Age Group, 2024 & 2032 (%)
- 9.1.2. Infants & Young Children
- 9.1.3. Adults
- 9.1.4. Older Adults (65+ years)

10. Respiratory Syncytial Virus Therapeutics Market - By Distribution Channel

10.1. Overview
- 10.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
- 10.1.2. Hospitals & Clinics
- 10.1.3. Retail Pharmacies
- 10.1.4. Online Pharmacies

11. Respiratory Syncytial Virus Therapeutics Market- By Geography

11.1. Introduction
- 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
11.2. North America
- 11.2.1. Overview
- 11.2.2. Respiratory Syncytial Virus Therapeutics Key Manufacturers in North America
- 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.2.4. North America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 11.2.5. North America Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 11.2.6. North America Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
- 11.2.7. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.2.8. The U.S.
  - 11.2.8.1. Overview
  - 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.8.3. U.S. Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.2.8.4. U.S. Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.2.8.5. U.S. Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.2.8.6. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.2.9. Canada
  - 11.2.9.1. Overview
  - 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.9.3. Canada Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.2.9.4. Canada Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.2.9.5. Canada Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.2.9.6. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3. Europe
- 11.3.1. Overview
- 11.3.2. Respiratory Syncytial Virus Therapeutics Key Manufacturers in Europe
- 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.3.4. Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 11.3.5. Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 11.3.6. Europe Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
- 11.3.7. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.8. Germany
  - 11.3.8.1. Overview
  - 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.8.3. Germany Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.3.8.4. Germany Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.3.8.5. Germany Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.3.8.6. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.9. UK
  - 11.3.9.1. Overview
  - 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.9.3. UK Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.3.9.4. UK Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.3.9.5. UK Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.3.9.6. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.10. France
  - 11.3.10.1. Overview
  - 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.10.3. France Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.3.10.4. France Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.3.10.5. France Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.3.10.6. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.11. Italy
  - 11.3.11.1. Overview
  - 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.11.3. Italy Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.3.11.4. Italy Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.3.11.5. Italy Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.3.11.6. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.12. Spain
  - 11.3.12.1. Overview
  - 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.12.3. Spain Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.3.12.4. Spain Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.3.12.5. Spain Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.3.12.6. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.13. The Netherlands
  - 11.3.13.1. Overview
  - 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.13.3. The Netherlands Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.3.13.4. The Netherlands Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.3.13.5. The Netherlands Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.3.13.6. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.14. Sweden
  - 11.3.14.1. Overview
  - 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.14.3. Sweden Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.3.14.4. Sweden Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.3.14.5. Sweden Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.3.14.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.15. Russia
  - 11.3.15.1. Overview
  - 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.15.3. Russia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.3.15.4. Russia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.3.15.5. Russia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.3.15.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.16. Poland
  - 11.3.16.1. Overview
  - 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.16.3. Poland Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.3.16.4. Poland Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.3.16.5. Poland Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.3.16.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.17. Rest of Europe
  - 11.3.17.1. Overview
  - 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.17.3. Rest of the Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.3.17.4. Rest of the Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.3.17.5. Rest of the Europe Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.3.17.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
- 11.4.1. Overview
- 11.4.2. Respiratory Syncytial Virus Therapeutics Key Manufacturers in Asia Pacific
- 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.4.4. APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 11.4.5. APAC Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 11.4.6. APAC Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
- 11.4.7. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.8. China
  - 11.4.8.1. Overview
  - 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.8.3. China Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.4.8.4. China Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.4.8.5. China Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.4.8.6. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.9. India
  - 11.4.9.1. Overview
  - 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.9.3. India Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.4.9.4. India Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.4.9.5. India Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.4.9.6. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.10. Japan
  - 11.4.10.1. Overview
  - 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.10.3. Japan Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.4.10.4. Japan Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.4.10.5. Japan Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.4.10.6. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.11. South Korea
  - 11.4.11.1. Overview
  - 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.11.3. South Korea Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.4.11.4. South Korea Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.4.11.5. South Korea Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.4.11.6. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.12. Australia
  - 11.4.12.1. Overview
  - 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.12.3. Australia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.4.12.4. Australia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.4.12.5. Australia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.4.12.6. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.13. Indonesia
  - 11.4.13.1. Overview
  - 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.13.3. Indonesia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.4.13.4. Indonesia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.4.13.5. Indonesia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.4.13.6. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.14. Thailand
  - 11.4.14.1. Overview
  - 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.14.3. Thailand Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.4.14.4. Thailand Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.4.14.5. Thailand Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.4.14.6. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.15. Philippines
  - 11.4.15.1. Overview
  - 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.15.3. Philippines Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.4.15.4. Philippines Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.4.15.5. Philippines Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.4.15.6. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.16. Rest of APAC
  - 11.4.16.1. Overview
  - 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.16.3. Rest of APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.4.16.4. Rest of APAC Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.4.16.5. Rest of APAC Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.4.16.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.5. Latin America (LATAM)
- 11.5.1. Overview
- 11.5.2. Respiratory Syncytial Virus Therapeutics Key Manufacturers in Latin America
- 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.5.4. LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 11.5.5. LATAM Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 11.5.6. LATAM Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
- 11.5.7. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.5.8. Brazil
  - 11.5.8.1. Overview
  - 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.8.3. Brazil Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.5.8.4. Brazil Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.5.8.5. Brazil Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.5.8.6. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.5.9. Mexico
  - 11.5.9.1. Overview
  - 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.9.3. Mexico Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.5.9.4. Mexico Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.5.9.5. Mexico Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.5.9.6. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.5.10. Argentina
  - 11.5.10.1. Overview
  - 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.10.3. Argentina Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.5.10.4. Argentina Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.5.10.5. Argentina Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.5.10.6. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.5.11. Colombia
  - 11.5.11.1. Overview
  - 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.11.3. Colombia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.5.11.4. Colombia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.5.11.5. Colombia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.5.11.6. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.5.12. Rest of LATAM
  - 11.5.12.1. Overview
  - 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.12.3. Rest of LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.5.12.4. Rest of LATAM Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.5.12.5. Rest of LATAM Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.5.12.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6. Middle East and Africa (MEA)
- 11.6.1. Overview
- 11.6.2. Respiratory Syncytial Virus Therapeutics Key Manufacturers in Middle East and Africa
- 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.6.4. MEA Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 11.6.5. MEA Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 11.6.6. MEA Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
- 11.6.7. MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.6.8. Saudi Arabia
  - 11.6.8.1. Overview
  - 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.8.3. Saudi Arabia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.6.8.4. Saudi Arabia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.6.8.5. Saudi Arabia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.6.8.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.6.9. United Arab Emirates
  - 11.6.9.1. Overview
  - 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.9.3. United Arab Emirates Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.6.9.4. United Arab Emirates Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.6.9.5. United Arab Emirates Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.6.9.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.6.10. Israel
  - 11.6.10.1. Overview
  - 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.10.3. Israel Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.6.10.4. Israel Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.6.10.5. Israel Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.6.10.6. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.6.11. Turkey
  - 11.6.11.1. Overview
  - 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.11.3. Turkey Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.6.11.4. Turkey Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.6.11.5. Turkey Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.6.11.6. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.6.12. Algeria
  - 11.6.12.1. Overview
  - 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.12.3. Algeria Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.6.12.4. Algeria Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.6.12.5. Algeria Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.6.12.6. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.6.13. Egypt
  - 11.6.13.1. Overview
  - 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.13.3. Egypt Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.6.13.4. Egypt Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.6.13.5. Egypt Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.6.13.6. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.6.14. Rest of MEA
  - 11.6.14.1. Overview
  - 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.14.3. Rest of MEA Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.6.14.4. Rest of MEA Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.6.14.5. Rest of MEA Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.6.14.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Respiratory Syncytial Virus Therapeutics Industry

12.1. Competitive Dashboard
- 12.1.1. Competitive Benchmarking
- 12.1.2. Competitive Positioning
12.2. Company Profiles
- 12.2.1. AstraZeneca plc
- 12.2.2. Sanofi S.A.
- 12.2.3. Pfizer Inc.
- 12.2.4. Moderna, Inc.
- 12.2.5. GSK plc
- 12.2.6. Merck & Co., Inc.
- 12.2.7. Johnson & Johnson
- 12.2.8. Novavax, Inc.
- 12.2.9. Bavarian Nordic A/S
- 12.2.10. Enanta Pharmaceuticals, Inc.
- 12.2.11. BioNTech SE
- 12.2.12. Meissa Vaccines, Inc.
- 12.2.13. Codagenix, Inc.
- 12.2.14. Alnylam Pharmaceuticals, Inc.
- 12.2.15. Vaxart, Inc.
- 12.2.16. Icosavax, Inc.

13. 360 Degree AnalystView

14. Appendix

14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us